The following is a review of current policy and proposed legislation related to health behavior indicators in North Carolina. It is not an endorsement of any policy or bill; it is meant to serve as a resource for policy makers, health care stakeholders, and other readers of the NCMJ.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.18043/ncm.83.4.284 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of Baseline Blood Zinc Levels on the Humoral Immune Response After COVID-19 mRNA Vaccination: A Prospective Study in a Japanese Population.
Vaccines (Basel)
November 2024
Department of Social and Environmental Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan.
Background/objectives: Although the protective effects of zinc against COVID-19 are documented, its impact on COVID-19 vaccine immunogenicity remains unknown.
Methods: We conducted a prospective study involving a cohort of 79 Japanese individuals (aged 21-56 years; comprising three subcohorts) and measured their serum zinc levels pre-vaccination and anti-SARS-CoV-2 IgM/IgG levels pre- and post-vaccination over 4 months.
Results: Serum zinc concentrations ranged between 74-140 and 64-113 μg/dL in male and female individuals, respectively, with one male and 11 female participants exhibiting subclinical zinc deficiency (60-80 μg/dL).
Improving the Performance of Electrotactile Brain-Computer Interface Using Machine Learning Methods on Multi-Channel Features of Somatosensory Event-Related Potentials.
Sensors (Basel)
December 2024
School of Electrical Engineering, University of Belgrade, 11000 Belgrade, Serbia.
Traditional tactile brain-computer interfaces (BCIs), particularly those based on steady-state somatosensory-evoked potentials, face challenges such as lower accuracy, reduced bit rates, and the need for spatially distant stimulation points. In contrast, using transient electrical stimuli offers a promising alternative for generating tactile BCI control signals: somatosensory event-related potentials (sERPs). This study aimed to optimize the performance of a novel electrotactile BCI by employing advanced feature extraction and machine learning techniques on sERP signals for the classification of users' selective tactile attention.
View Article and Find Full Text PDFAcoustic Wave Sensor Detection of an Ovarian Cancer Biomarker with Antifouling Surface Chemistry.
Sensors (Basel)
December 2024
Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, ON M5S 3H6, Canada.
Ovarian cancer (OC) must be detected in its early stages when the mortality rate is the lowest to provide patients with the best chance of survival. Lysophosphatidic acid (LPA) is a critical OC biomarker since its levels are elevated across all stages and increase with disease progression. This paper presents an LPA assay based on a thickness shear mode acoustic sensor with dissipation monitoring that involves a new thiol molecule 3-(2-mercaptoethanoxy)propanoic acid (HS-MEG-COOH).
View Article and Find Full Text PDFA Zeolitic Imidazolate Framework-Based Antimicrobial Peptide Delivery System with Enhanced Anticancer Activity and Low Systemic Toxicity.
Pharmaceutics
December 2024
Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830046, China.
Background: The clinical efficacies of anticancer drugs are limited by non-selective toxic effects on healthy tissues and low bioavailability in tumor tissue. Therefore, the development of vehicles that can selectively deliver and release drugs at the tumor site is critical for further improvements in patient survival.
Methods: We prepared a CEC nano-drug delivery system, CEC@ZIF-8, with a zeolite imidazole framework-8 (ZIF-8) as a carrier, which can achieve the response of folate receptor (FR).
Model-Based Dose Selection of a Sphingosine-1-Phosphate Modulator, Etrasimod, in Patients with Various Degrees of Hepatic Impairment.
Pharmaceutics
December 2024
Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Etrasimod is a newly FDA-approved Sphingosine-1-Phosphate modulator indicated for moderate and severe ulcerative colitis. It is extensively metabolized in the liver via the cytochrome P450 system and may accumulate markedly in patients with hepatic dysfunction, exposing them to toxicity. The aim of the current study is to utilize a physiologically-based pharmacokinetic modeling approach to evaluate the impact of hepatic impairment on the pharmacokinetic behavior of etrasimod and to appropriately select dosage regimens for patients with chronic liver disease; Methods: PK-Sim was used to develop the etrasimod PBPK model, which was verified using clinical data from healthy subjects and subsequently adapted to reflect the physiological changes associated with varying degrees of hepatic dysfunction; Results: Simulations indicated that hepatic clearance of etrasimod is clearly reduced in patients with Child-Pugh B and C liver impairment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!